DURHAM, NC - Treatment for full-term babies born with hypoxic-ischemic– brain damage due to blood and oxygen deprivation injuries is currently limited to therapeutic cooling to improve outcomes. There is no treatment for pre-term babies; however, a new study appearing in the latest issue of STEM CELLS Translational Medicine may lead to therapies that repair damage from hypoxia-ischemia.
You are here
Press Releases from AlphaMed Press
March 31, 2016
Durham, NC – A new study in STEM CELLS Translational Medicine offers people with genetic hearing loss the promise of a new therapy that just might outperform artificial cochlear implants.
Implants currently are the most effective way to treat sensorineural hearing loss, a type of hereditary hearing loss caused by genetic mutations in the hair cells — the sensory receptors of the auditory system, found in the inner ear (the cochlea). A cochlear implant helps transfer sound to the patient’s hearing nerves and enables them to hear. But many researchers believe that stem cells could offer a more comprehensive and better fix for this problem.
March 22, 2016
Durham, NC – A study recently published in STEM CELLS Translational Medicine points the way to a new, potentially restorative treatment for age-related or type II osteoporosis. When a single dose of a certain type of stem cell, called mesenchymal stromal cells (MSCs), was injected into mice with the disease, long-term bone engraftment and quality bone growth resulted. As an added benefit, the cells protected existing bone from damage.
March 9, 2016
Durham, NC – A new type of engineered stem cell could transform how Alzheimer's disease (AD) is treated and perhaps even stop the disease in its tracks. In a study recently published in STEM CELLS Translational Medicine, a team of University of Michigan researchers describe how they revved up the levels of a protein called IGF-I in a line of neuronal stem cells (NSCs), which resulted in the NSCs producing brain cells that were both resistant to AD and capable of restoring AD-ravaged cells to normal.
November 12, 2015
Durham, NC – A new study appearing in STEM CELLS Translational Medicine (SCTM) describes a highly efficient, protein-based method for turning fibroblasts — the most common cells in connective tissue — into cardiac progenitor cells (CPCs). The results could lead to a much-needed new source of cells for regenerating the heart. Equally exciting is that the technology also converts the fibroblasts directly to CPCs, skipping an in-between and significantly speeding up the process.
September 3, 2015
Durham, NC, Sep. 3, 2015 /PRNewswire-iReach/ -- According to a study released in the latest issue of STEM CELLS Translational Medicine, a German team of researchers discovered that extracellular vesicles (EVs), tiny membrane-enclosed structures that travel between cells, seem to work as well as adult stem cells to help the brain recover from a stroke.
August 27, 2015
Durham, NC, Aug. 27, 2015 /PRNewswire-iReach/ -- A new study appearing in STEM CELLS Translational Medicine indicates that stem cell injections helped rats live almost a third longer than normal. In addition, the treated animals remained both physically and mentally active longer throughout their life spans.
August 4, 2015
DURHAM, N.C., Aug. 3, 2015 /PRNewswire-iReach/ -- A study released today in STEM CELLS Translational Medicine shows the promise of stem cells for growing new cartilage to replace the tissue damaged by osteoarthritis or injury. That's good news for the rapidly growing number of people undergoing knee and hip replacements each year – nearly a million (645,000 hips and 300,000 knees) in the U.S. alone, according to a 2011 report from the American Academy of Orthopaedic Surgeons.
July 28, 2015
DURHAM, N.C., July 27, 2015 /PRNewswire-iReach/ -- A new clinical trial to test how a high dose of stem cells delivered via a method called "retrograde coronary sinus infusion" affects end stage heart failure patients is showing promising results. The method involves giving the cells backwards (retrograde) through the heart through the main vein (the coronary sinus).
June 24, 2015
DURHAM, N.C., June 23, 2015 /PRNewswire-iReach/ -- To date, the only definitive treatment for heart failure – an organ transplant – is hampered by both the limited number of organ donors and the potential for the patient's body to reject the new heart. However, findings of a study published in STEM CELLS Translational Medicine demonstrate the promise in regenerating cardiac tissue using engineered patches made up of a mixture of fibrin and mesenchymal stem cells (MSCs) derived from human umbilical cord blood.
